Covalon Technologies Ltd. CVALF OTC

Other OTC • Healthcare • Biotechnology • CA • USD

SharesGrow Score

70/100

3/6 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Covalon Technologies Ltd. (CVALF) reported total assets of $36.12M and total liabilities of $5.4M for fiscal year 2025, resulting in total equity of $30.73M.

The company held $17.37M in cash and short-term investments. Total debt stood at $2.25M, with net debt of $-15.11M. The Debt-to-Equity (D/E) ratio was 0.07 (conservative).

Current ratio is 8.36, indicating strong short-term liquidity.

Criteria supported by this page:

HEALTH (100/100, Pass) — Debt-to-Equity of 0.07, current ratio of 8.36 — balance sheet is strong
MOAT (50/100) — Total assets $36.12M and equity $30.73M support the company's competitive scale
VALUE (75/100) — Debt-to-Equity 0.07 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 68/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score

70/100

SG Score

View full scorecard →

✓

VALUE

75/100

Price-to-Earnings & upside

→ Valuation

—

FUTURE

N/A

No coverage

PAST

50/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

Proven by this page

MOAT

50/100

→ Income

✓

GROWTH

100/100

→ Income

INCOME

45/100

→ Income

Covalon Technologies Ltd. Balance Sheet History

Metric	FY2025	FY2024	FY2023	FY2022
Total Assets	$36.12M	$31.81M	$24.9M	$30.38M
Total Liabilities	$5.4M	$4.3M	$6.11M	$6.15M
Total Debt	$2.25M	$901.67K	$1.56M	$2.17M
Cash & Investments	$17.37M	$16.75M	$8.79M	$14.06M
Total Stockholders Equity	$30.73M	$27.5M	$18.79M	$24.23M